← Issue №9/ week of Aug 30, 2026/Hepatology

Recompensation After Etiologic Cure in U.S. Veterans with HCV-Related Decompensated Cirrhosis.

From GI Signals issue №9: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

Hepatology retrospective · n=1,213 · Aug 24, 2026 · Clin Gastro Hep · IF 16.2

Recompensation After Etiologic Cure in U.S. Veterans with HCV-Related Decompensated Cirrhosis.

New evidencecirrhosisviral hepatitisasciteshepatocellular carcinoma
Clinical takeawayMonitor HCV-related decompensated cirrhosis patients post-DAA therapy for ascites resolution and liver synthetic function (albumin, platelet count) as markers of potential recompensation, which is associated with improved survival compared to those who did not recompensate.
What it found13% of HCV-related decompensated cirrhosis patients achieved recompensation (per Baveno VII criteria: resolution of ascites, no variceal bleeding, and no hepatic encephalopathy) within 24 months of DAA therapy, with higher baseline albumin and platelet count ≥110 ×10ˆ9/L predicting higher likelihood.
ContextConfirms and quantifies the feasibility of recompensation in HCV-related decompensated cirrhosis post-DAA therapy, aligning with Baveno VII criteria and identifying practical clinical markers. However, only 13% achieved recompensation, highlighting the need for further research to improve outcomes.
Measured against the standard of care· AASLD 2021 Practice Guidance (Biggins et al., Hepatology) / AGA Clinical Practice Update 2025 (Orman et al., Gastroenterology 2025;169(7):1547-1557)

Decision at stakethe likelihood of recompensation after HCV cure in decompensated cirrhosis

No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.

Our full summary of this standard

Perform a diagnostic paracentesis as soon as possible in any patient with new-onset ascites that can be sampled. Also perform one in any patient with cirrhosis and ascites who is admitted to hospital. AASLD 2021 says this applies to emergent admission for any reason. AGA 2025 BPA 2 names admission for ascites- or encephalopathy-related symptoms. The tap rules out SBP even without signs of infection, because up to one-third of SBP is asymptomatic. Repeat it whenever signs, symptoms or labs suggest infection, and in tense ascites with AKI. Paracentesis is safe with coagulopathy: INR >1.5 or platelets <50×10^9/L is not a contraindication, and routine FFP or platelet transfusion is not recommended. Possible exceptions are DIC, and uremia with thrombocytopenia, where desmopressin may be considered. Initial fluid testing: neutrophil (PMN) count, total protein, and ascitic albumin with a same-day serum albumin to calculate the SAAG. AGA 2025 adds Gram stain and culture to the initial panel for new-onset ascites and hospitalized patients. AASLD 2021 treats culture as part of the SBP workup rather than the routine panel. Either way, inoculate ≥10 mL into aerobic and anaerobic blood-culture bottles at the bedside before antibiotics. Amylase, cytology, glucose, LDH, AFB/ADA and triglycerides are ordered only for a clinical reason. SAAG ≥1.1 g/dL means portal hypertension (~97% accuracy). SAAG <1.1 g/dL points to a non-portal-hypertensive cause: carcinomatosis, TB peritonitis, nephrotic syndrome, pancreatic or chylous ascites. Within high-SAAG ascites, total protein <2.5 g/dL suggests cirrhosis (also massive liver metastases or late Budd-Chiari). Total protein ≥2.5 g/dL suggests a cardiac or postsinusoidal cause (heart failure, portal vein thrombosis, SOS, early Budd-Chiari), so work up with echocardiography, hepatic-vein Doppler or right-heart catheterization. SBP is diagnosed by ascitic PMN >250/mm^3, with or without a positive culture, once a surgically treatable source has been excluded. SBE is diagnosed by pleural fluid PMN >250/mm^3 in a hepatic hydrothorax after pneumonia and other secondary causes are excluded. It is treated with antibiotics and no chest tube.

AASLD 2021 Practice Guidance (Biggins et al., Hepatology) / AGA Clinical Practice Update 2025 (Orman et al., Gastroenterology 2025;169(7):1547-1557) · reviewed 2026-10-11 ↗
Goyes D … Garcia-Tsao G · Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association · IF 16.2 · PubMed ↗Permalink
← Read the whole of issue №9 Every paper GI Signals surfaces gets a page like this one. All issues